A French company is testing a new drug to treat mild to moderate Alzheimer’s disease in a 12-week trial at about 40 sites around the world, including 34 in the United States.

Developed by Sanofi-Synthelabo, Inc., the nameless drug may reduce the accumulation of destructive plaque that impairs Alzheimer’s patients’ memory.

The drug appeared to improve memory and learning in animals in past research.